Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus:: Clindamycin susceptibility as a surrogate indicator

被引：29

作者：

Fuchs, PC ^{[1
]}

Barry, AL ^{[1
]}

Brown, SD ^{[1
]}

机构：

[1] Inst Clin Microbiol, Wilsonville, OR 97070 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 10期

关键词：

D O I：

10.1128/AAC.44.10.2880-2882.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Of 516 Staphylococcus aureus strains tested, 97.1% were susceptible to quinupristin-dalfopristin, which,vas bactericidal for 22 (56%) of the 39 strains tested, comparable to vancomycin. All 17 clindamycin and macrolide-resistant strains were inhibited but not killed bg quinupristin-dalfopristin, whereas all 22 clindamycin-susceptible strains (5 were macrolide resistant) were killed.

引用

收藏

页码：2880 / 2882

页数：3

相关论文

共 18 条

[1] RP-59500, A NEW STREPTOGRAMIN HIGHLY-ACTIVE AGAINST RECENT ISOLATES OF NORTH-AMERICAN STAPHYLOCOCCI [J].

ARCHER, GL ;

AUGER, P ;

DOERN, GV ;

FERRARO, MJ ;

FUCHS, PC ;

JORGENSEN, JH ;

LOW, DE ;

MURRAY, PR ;

RELLER, LB ;

STRATTON, CW ;

WENNERSTEN, CB ;

MOELLERING, RC .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1993, 16 (03) :223-226

[2] The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans [J].

Bergeron, M ;

Montay, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :129-138

[3] INVITRO ACTIVITY OF RP 59500, A NEW SEMISYNTHETIC STREPTOGRAMIN ANTIBIOTIC, AGAINST GRAM-POSITIVE BACTERIA [J].

BRUMFITT, W ;

HAMILTONMILLER, JMT ;

SHAH, S .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :29-37

[4] A PHASE-I, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE TOLERANCE AND PHARMACOKINETIC BEHAVIOR OF RP 59500 [J].

ETIENNE, SD ;

MONTAY, G ;

LELIBOUX, A ;

FRYDMAN, A ;

GARAUD, JJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :123-131

[5] CRITICAL INFLUENCE OF RESISTANCE TO STREPTOGRAMIN B-TYPE ANTIBIOTICS ON ACTIVITY OF RP-59500 (QUINUPRISTIN-DALFOPRISTIN) IN EXPERIMENTAL ENDOCARDITIS DUE TO STAPHYLOCOCCUS-AUREUS [J].

FANTIN, B ;

LECLERCQ, R ;

MERLE, Y ;

SAINTJULIEN, L ;

VEYRAT, C ;

DUVAL, J ;

CARBON, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :400-405

[6] INVITRO ACTIVITY OF RP-59500, A SEMISYNTHETIC INJECTABLE PRISTINAMYCIN, AGAINST STAPHYLOCOCCI, STREPTOCOCCI, AND ENTEROCOCCI [J].

FASS, RJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :553-559

[7] THE INVITRO ACTIVITY OF RP 59500 AGAINST GRAM-POSITIVE COCCI [J].

GOTO, S ;

MIYAZAKI, S ;

KANEKO, Y .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :25-28

[8] Quinupristin-dalfopristin (RP 59500): An injectable streptogramin combination [J].

Griswold, MW ;

Lomaestro, BM ;

Briceland, LL .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (17) :2045-2053

[9] INVITRO ACTIVITY OF STREPTOGRAMIN RP 59500 AGAINST STAPHYLOCOCCI, INCLUDING BACTERICIDAL KINETIC-STUDIES [J].

HOBAN, DJ ;

WESHNOWESKI, B ;

PALATNICK, L ;

ZHANEL, CG ;

DAVIDSON, RJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :59-65

[10] Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains [J].

Jones, ME ;

Visser, MR ;

Klootwijk, M ;

Heisig, P ;

Verhoef, J ;

Schmitz, FJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :421-423